These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32131689)

  • 41. Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease.
    Jortveit J; Halvorsen S; Kaldal A; Pripp AH; Govatsmark RES; Langørgen J
    BMC Cardiovasc Disord; 2019 Mar; 19(1):71. PubMed ID: 30922234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Higher risk of major adverse cardiac events after acute myocardial infarction in patients with schizophrenia.
    Attar R; Wester A; Koul S; Eggert S; Polcwiartek C; Jernberg T; Erlinge D; Andell P
    Open Heart; 2020 Sep; 7(2):. PubMed ID: 32994353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
    Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.
    Du L; Cheng Z; Zhang Y; Li Y; Mei D
    Eur J Prev Cardiol; 2017 Jun; 24(9):962-970. PubMed ID: 28436725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
    Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
    BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
    Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine.
    Gao ZY; Xu H; Shi DZ; Wen C; Liu BY
    J Ethnopharmacol; 2012 Jun; 141(2):578-83. PubMed ID: 21924336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Harrison RW; Simon D; Miller AL; de Lemos JA; Peterson ED; Wang TY
    Am Heart J; 2016 Aug; 178():95-101. PubMed ID: 27502856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction.
    Hioki H; Motoki H; Izawa A; Kashima Y; Miura T; Ebisawa S; Tomita T; Miyashita Y; Koyama J; Ikeda U
    Heart Vessels; 2016 May; 31(5):687-93. PubMed ID: 25863805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Left ventricular ejection fraction assessment among patients with acute myocardial infarction and its association with hospital quality of care and evidence-based therapy use.
    Miller AL; Dib C; Li L; Chen AY; Amsterdam E; Funk M; Saucedo JF; Wang TY
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):662-71. PubMed ID: 22949495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guideline adherence and long-term clinical outcomes in patients with acute myocardial infarction: a Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) substudy.
    Wada H; Ogita M; Suwa S; Nakao K; Ozaki Y; Kimura K; Ako J; Noguchi T; Yasuda S; Fujimoto K; Nakama Y; Morita T; Shimizu W; Saito Y; Hirohata A; Morita Y; Inoue T; Okamura A; Mano T; Hirata K; Tanabe K; Shibata Y; Owa M; Tsujita K; Funayama H; Kokubu N; Kozuma K; Uemura S; Toubaru T; Saku K; Oshima S; Nishimura K; Miyamoto Y; Ogawa H; Ishihara M;
    Eur Heart J Acute Cardiovasc Care; 2020 Dec; 9(8):939-947. PubMed ID: 31976749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
    Chrischilles EA; Schneider KM; Schroeder MC; Letuchy E; Wallace RB; Robinson JG; Brooks JM
    J Am Geriatr Soc; 2016 Mar; 64(3):526-35. PubMed ID: 26928940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving the Prescribing Gap For Guideline Recommended Medications Post Myocardial Infarction.
    Wilkins B; Hullikunte S; Simmonds M; Sasse A; Larsen P; Harding SA
    Heart Lung Circ; 2019 Feb; 28(2):257-262. PubMed ID: 29523466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term secondary prevention and outcome following acute coronary syndrome: real-world results from the Swedish Primary Care Cardiovascular Database.
    Bentzel S; Ljungman C; Hjerpe P; Schiöler L; Manhem K; Bengtsson Boström K; Kahan T; Mourtzinis G
    Eur J Prev Cardiol; 2024 May; 31(7):812-821. PubMed ID: 38135289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry.
    Tea V; Bonaca M; Chamandi C; Iliou MC; Lhermusier T; Aissaoui N; Cayla G; Angoulvant D; Ferrières J; Schiele F; Simon T; Danchin N; Puymirat E;
    Eur J Prev Cardiol; 2019 Mar; 26(4):411-419. PubMed ID: 30354737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.